Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...
Pfizer's mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported.
The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...
In a large-scale trial, modRNA was significantly better at preventing confirmed flu cases than a typical seasonal flu shot.
Pfizer-funded study finds a next-gen mRNA flu shot works better against current strains — but causes more short-term side ...
Amid uncertainty over how the Trump administration would approach mRNA COVID-19 vaccines for the upcoming respiratory virus season, the FDA has approved updated shots from Pfizer and Moderna. But ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback